Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

Helen J Ross, George R. Blumenschein, Joseph Aisner, Nevena Damjanov, Afshin Dowlati, Jennifer Garst, James R. Rigas, Michael Smylie, Habib Hassani, Kimberly E. Allen, Lance Leopold, Tal Z. Zaks, Frances A. Shepherd

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history. Experimental Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance. Patients could have had a maximum of one prior systemic therapy (chemotherapy or biological therapy) for NSCLC. Safety and activity were assessed every 4 and 8 weeks, respectively. Tumors were analyzed for EGFR and HER2 mutations and/or amplifications. Results: Of 75 patients in the nontargeted population, 1 (1.3%) had partial response and 16 (21%) had stable disease of ≥24 weeks. No complete or partial responses were observed in 56 patients in the targeted population; 14 (25%) had stable disease of ≥24 weeks. No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification. No mutations in HER2 were found. One of two patients with HER2 amplification had a 51% decrease in tumor size; however, this response was unconfirmed. The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia. Adverse events were similar across dosing regimens. Conclusions: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups. Lapatinib monotherapy did not induce a significant number of tumor regressions in NSCLC. Further studies may be warranted to determine whether lapatinib is active in combination with other agents in the treatment of NSCLC.

Original languageEnglish (US)
Pages (from-to)1938-1949
Number of pages12
JournalClinical Cancer Research
Volume16
Issue number6
DOIs
StatePublished - Mar 15 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Multicenter Studies
Appointments and Schedules
Epidermal Growth Factor Receptor
Mutation
Bronchiolo-Alveolar Adenocarcinoma
erbB-1 Genes
Drug Therapy
Neoplasms
Biological Therapy
lapatinib
Gene Amplification
Anorexia
Exanthema
Protein-Tyrosine Kinases
Nausea
Population
Fatigue
Diarrhea
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. / Ross, Helen J; Blumenschein, George R.; Aisner, Joseph; Damjanov, Nevena; Dowlati, Afshin; Garst, Jennifer; Rigas, James R.; Smylie, Michael; Hassani, Habib; Allen, Kimberly E.; Leopold, Lance; Zaks, Tal Z.; Shepherd, Frances A.

In: Clinical Cancer Research, Vol. 16, No. 6, 15.03.2010, p. 1938-1949.

Research output: Contribution to journalArticle

Ross, HJ, Blumenschein, GR, Aisner, J, Damjanov, N, Dowlati, A, Garst, J, Rigas, JR, Smylie, M, Hassani, H, Allen, KE, Leopold, L, Zaks, TZ & Shepherd, FA 2010, 'Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer', Clinical Cancer Research, vol. 16, no. 6, pp. 1938-1949. https://doi.org/10.1158/1078-0432.CCR-08-3328
Ross, Helen J ; Blumenschein, George R. ; Aisner, Joseph ; Damjanov, Nevena ; Dowlati, Afshin ; Garst, Jennifer ; Rigas, James R. ; Smylie, Michael ; Hassani, Habib ; Allen, Kimberly E. ; Leopold, Lance ; Zaks, Tal Z. ; Shepherd, Frances A. / Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 6. pp. 1938-1949.
@article{7f9d85b549714e289b3653926693513b,
title = "Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer",
abstract = "Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history. Experimental Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance. Patients could have had a maximum of one prior systemic therapy (chemotherapy or biological therapy) for NSCLC. Safety and activity were assessed every 4 and 8 weeks, respectively. Tumors were analyzed for EGFR and HER2 mutations and/or amplifications. Results: Of 75 patients in the nontargeted population, 1 (1.3{\%}) had partial response and 16 (21{\%}) had stable disease of ≥24 weeks. No complete or partial responses were observed in 56 patients in the targeted population; 14 (25{\%}) had stable disease of ≥24 weeks. No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification. No mutations in HER2 were found. One of two patients with HER2 amplification had a 51{\%} decrease in tumor size; however, this response was unconfirmed. The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia. Adverse events were similar across dosing regimens. Conclusions: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups. Lapatinib monotherapy did not induce a significant number of tumor regressions in NSCLC. Further studies may be warranted to determine whether lapatinib is active in combination with other agents in the treatment of NSCLC.",
author = "Ross, {Helen J} and Blumenschein, {George R.} and Joseph Aisner and Nevena Damjanov and Afshin Dowlati and Jennifer Garst and Rigas, {James R.} and Michael Smylie and Habib Hassani and Allen, {Kimberly E.} and Lance Leopold and Zaks, {Tal Z.} and Shepherd, {Frances A.}",
year = "2010",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-08-3328",
language = "English (US)",
volume = "16",
pages = "1938--1949",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

AU - Ross, Helen J

AU - Blumenschein, George R.

AU - Aisner, Joseph

AU - Damjanov, Nevena

AU - Dowlati, Afshin

AU - Garst, Jennifer

AU - Rigas, James R.

AU - Smylie, Michael

AU - Hassani, Habib

AU - Allen, Kimberly E.

AU - Leopold, Lance

AU - Zaks, Tal Z.

AU - Shepherd, Frances A.

PY - 2010/3/15

Y1 - 2010/3/15

N2 - Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history. Experimental Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance. Patients could have had a maximum of one prior systemic therapy (chemotherapy or biological therapy) for NSCLC. Safety and activity were assessed every 4 and 8 weeks, respectively. Tumors were analyzed for EGFR and HER2 mutations and/or amplifications. Results: Of 75 patients in the nontargeted population, 1 (1.3%) had partial response and 16 (21%) had stable disease of ≥24 weeks. No complete or partial responses were observed in 56 patients in the targeted population; 14 (25%) had stable disease of ≥24 weeks. No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification. No mutations in HER2 were found. One of two patients with HER2 amplification had a 51% decrease in tumor size; however, this response was unconfirmed. The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia. Adverse events were similar across dosing regimens. Conclusions: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups. Lapatinib monotherapy did not induce a significant number of tumor regressions in NSCLC. Further studies may be warranted to determine whether lapatinib is active in combination with other agents in the treatment of NSCLC.

AB - Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history. Experimental Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance. Patients could have had a maximum of one prior systemic therapy (chemotherapy or biological therapy) for NSCLC. Safety and activity were assessed every 4 and 8 weeks, respectively. Tumors were analyzed for EGFR and HER2 mutations and/or amplifications. Results: Of 75 patients in the nontargeted population, 1 (1.3%) had partial response and 16 (21%) had stable disease of ≥24 weeks. No complete or partial responses were observed in 56 patients in the targeted population; 14 (25%) had stable disease of ≥24 weeks. No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification. No mutations in HER2 were found. One of two patients with HER2 amplification had a 51% decrease in tumor size; however, this response was unconfirmed. The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia. Adverse events were similar across dosing regimens. Conclusions: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups. Lapatinib monotherapy did not induce a significant number of tumor regressions in NSCLC. Further studies may be warranted to determine whether lapatinib is active in combination with other agents in the treatment of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=77949694139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949694139&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-3328

DO - 10.1158/1078-0432.CCR-08-3328

M3 - Article

C2 - 20215545

AN - SCOPUS:77949694139

VL - 16

SP - 1938

EP - 1949

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -